Literature DB >> 2766299

Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer.

D T Kiang1, R E Kollander, T Thomas, B J Kennedy.   

Abstract

Development of resistance to hormonal therapy in breast cancer is frequently associated with a decline or loss of cellular estrogen receptors. Agents which up-regulate the receptor may reduce the incidence of hormonal resistance. Antiestrogens at concentrations ranging from 0.1 to 1 microM produced a 2- to 4-fold increase of estrogen receptors in MCF-7 and T-47D breast cancer cells. This increase, which occurred as early as 3 h and was sustained throughout the 4 days of continuous exposure to tamoxifen, was primarily due to an enhancement in receptor synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766299

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Authors:  Mary M Heckler; Hemang Thakor; Cara C Schafer; Rebecca B Riggins
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

3.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

Authors:  S Dauvois; P S Danielian; R White; M G Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

4.  Variations in amplification and expression of the ornithine decarboxylase gene in human breast cancer cells.

Authors:  T Thomas; D T Kiang; O A Jänne; T J Thomas
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

5.  Cell cycle expression of steroid receptors determined by image analysis on human breast cancer cell line: a hypothesis on the effects of antiestrogens.

Authors:  P Rostagno; C Caldani; B Lahlou
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

Authors:  R A McClelland; D L Manning; J M Gee; E Anderson; R Clarke; A Howell; M Dowsett; J F Robertson; R W Blamey; A E Wakeling; R I Nicholson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins.

Authors:  David M Lonard; Sophia Y Tsai; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

8.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

9.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.

Authors:  C A Encarnación; D R Ciocca; W L McGuire; G M Clark; S A Fuqua; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.

Authors:  Sreeja Sreekumar; Kevin M Levine; Matthew J Sikora; Jian Chen; Nilgun Tasdemir; Dorothy Carter; David J Dabbs; Carolin Meier; Ahmed Basudan; David Boone; Priscilla F McAuliffe; Rachel C Jankowitz; Adrian V Lee; Jennifer M Atkinson; Steffi Oesterreich
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.